



# Países participando en GLASS

Hasta 17 de Noviembre 2017\*



- Enrolment completed (n=48)
- Enrolment in progress (n=9)

\* Call for country enrolment issued on 21 March 2016



# Gestión de la información Y análisis de datos en GLASS

Carmem Lucia Pessoa-Silva ([pessoasilvacl@who.int](mailto:pessoasilvacl@who.int))

*Red Latino Americana de Vigilancia de Resistencia a los Antimicrobianos -  
ReLAVRA*

*Montevideo, 28-30 Nov 2017*

# Core components for national surveillance systems



## Surveillance sites



## National reference laboratory (NRL)




**National Coordinating  
Centre to report to the  
national body in charge of  
strategies to contain AMR**


# GLASS IT platform



- To collect aggregated data throughout normalized files upload
- To produce reports and metrics based on collected data
- Hosted in WHO server




# GLASS reporting timeline: 2016-2017





➔ Go to <https://extranet.who.int/glass/portal>

➔ Log in with user name and password



A screenshot of a web browser showing the GLASS login page. The address bar at the top displays the URL <https://extranet.who.int/glass/portal/>. The page itself features the GLASS logo on the left, which includes the text "GLASS" and "Global AMR Surveillance System". In the center, there is a "Log in" form. It contains two input fields: one for "User name" and one for "Password", both represented by empty text boxes. Below these fields is a "Log in" button with a blue gradient. At the bottom of the form, there is a link labeled "Forgot your password?".

# GLASSware: the GLASS IT platform





Global Antimicrobial Resistance Surveillance System



World Health Organization

MY ACCOUNT ▾

LOGOUT

## Welcome to the WHO GLASS portal!

This is a platform for global data sharing on antimicrobial resistance worldwide. It has been launched by WHO as part of the implementation of the Global Action Plan on Antimicrobial Resistance (AMR). The data will help to inform national, regional and global decision-making, strategies and advocacy.

GLASS will initially focus on bacterial pathogens in humans. It will also collect information on countries' progress in establishing national AMR surveillance systems. GLASS will then be progressively expanded to include other types of AMR-related surveillance, such as the food chain, the environment and antimicrobial use and will build links with other global surveillance systems.

Antibacterial resistance in humans

Antimicrobial consumption

eGASP

EAR

Leprosy

Tricycle

Beta-version → end of 2017

2018

# GLASSware: the GLASS IT platform



The screenshot shows the homepage of the WHO GLASS portal. At the top left is the GLASS logo. In the center is the title "Global Antimicrobial Resistance Surveillance System". To the right is the World Health Organization logo. A navigation bar at the top includes "MY ACCOUNT" with a dropdown arrow and "LOGOUT". Below the header is a main section with the heading "Welcome to the WHO GLASS portal!". A text paragraph describes the platform's purpose and focus. At the bottom left, a button labeled "Antibacterial resistance in humans" is highlighted with a red mouse cursor pointing to it. The year "2018" is visible in the bottom right corner.

This is a platform for global data sharing on antimicrobial resistance worldwide. It has been launched by WHO as part of the implementation of the Global Action Plan on Antimicrobial Resistance (AMR). The data will help to inform national, regional and global decision-making, strategies and advocacy.

GLASS will initially focus on bacterial pathogens in humans. It will also collect information on countries' progress in establishing national AMR surveillance systems. GLASS will then be progressively expanded to include other types of AMR-related surveillance, such as the food chain, the environment and antimicrobial use and will build links with other global surveillance systems.

**Surveillance of antibacterial resistance in humans**

GLASS  
Global AMR Surveillance System

World Health Organization

HOME MENU COUNTRY LOGOUT

GLASS welcomes the participation of all countries. Countries are invited to provide information on the status of implementation of national AMR surveillance and upload data on ABR, following the definitions provided in the GLASS: Manual for early implementation.

This database enables to:

- upload, manage and submit data
- access upload history
- access and download previously submitted data
- generate data reports

To continue, please read Terms of Use and complete the following information:

**Country information**

**GLASS implementation questionnaire**

GLASS implementation questionnaire (\*.pdf)  
Questions related to the use of web-based internet GLASS platform should be sent to the email address: glass@who.int

**Aggregated AMR data**

Call for data on antimicrobial resistance will be open from July 1st 2016 to June 30th 2017

Data upload      Upload history      AMR data base      Denominator Questionnaire      Reports

Add an isolate      Data upload      Upload history      AMR data base      Denominator Questionnaire      Reports

For further information: [glass@who.int](mailto:glass@who.int)

## Antibacterial resistance in humans

→ GLASS focal points registration and submission of data on implementation of national AMR surveillance programmes

→ Aggregated AMR data: upload, validation and analysis

# Data submission



Health topics Data Media centre Publications Countries **Programmes** Governance

Surveillance of antibacterial resistance in humans

World Health Organization

## Antimicrobial resistance

### GLASS documents and tools

#### GLASS enrolment and data management

Guide to uploading aggregated antimicrobial resistance data

Download French PDF  
 pdf, 1.56Mb

Guide to preparing aggregated antimicrobial resistance data files

Download French PDF  
 pdf, 569kb

Guide to enrolment for antimicrobial resistance national focal points

Download French PDF  
 pdf, 582kb

#### Implementation questionnaire

Download French PDF  
 pdf, 149kb

Guide to completing the GLASS implementation questionnaire

To upload your data files please follow the steps below :

- Indicate which file you are going to upload (RIS or Sample file)
- Indicate the period of submission (January to December by default)
- Indicate the specimen(s) included in your data file
- Upload your file
- Click on "Load"

File type: RIS Please upload your RIS file first, then your Sample file.

Country: [REDACTED]

Year: 2009 Start: January End: December

Batch ID: Data Set 1

Specimen:  
 Blood  
 Genital  
 Stool  
 Urine

File: Choose File no file selected

Load

# Datos de implementación



Surveillance of antibacterial resistance in humans



HOME

MENU ▾

USER\_TEST1

GLASS welcomes the participation of all countries. Countries are invited to provide information on the status of implementation of national surveillance and upload data on ABR, following the definitions provided in the GLASS Manual for early implementation.

This database enables to:

- upload, manage and submit data
- access upload history
- access and download previously submitted data
- generate data reports

To continue, please read Terms of Use and complete the following information:



[Country information](#)



[GLASS implementation questionnaire](#)

GLASS Implementation questionnaire (\*.pdf)


Questions related to the use of web-based internet GLASS platform should be sent to the email address: glass@who.int

|   | Region : WHO | Region, Country : | Batch Id : All, 2016 |
|---|--------------|-------------------|----------------------|
| <b>Year</b>   |              |                   | 2016                 |
| <b>Population (thousands)</b>   |              |                   | 5503                 |
| <b>National Coordination Centre has been established</b>  |              |                   | Yes                  |
| <b>Focal Point for GLASS has been assigned</b>  |              |                   | Yes                  |
| <b>National plans to implement and strengthen AMR surveillance</b>  |              |                   | No                   |
| <b>National Reference Laboratory has been designated to support national AMR surveillance</b>                     |              |                   | Yes                  |
| <b>National Reference laboratory does participate in an external quality assurance scheme</b>                     |              |                   | Yes                  |
| <b>AST standards applied in the country : EUCAST</b>  |              |                   | Yes                  |
| <b>AST standards applied in the country : CLSI</b>  |              |                   | No                   |
| <b>AMR surveillance standards and guidelines that incorporate GLASS standards available in the country</b>        |              |                   | Yes                  |
| <b>National programme organize and run external quality assurance for all laboratories participating in GLASS</b> |              |                   | No                   |
| <b>External quality assurance cover both bacterial identification and AST</b>                                     |              |                   | ND                   |
| <b>All priority pathogens listed in the GLASS manual covered by the EQA</b>                                       |              |                   | ND                   |
| <b>Number of hospitals</b>  |              |                   | ND                   |
| <b>Number of outpatient facilities</b>  |              |                   | ND                   |
| <b>Number of reporting hospitals</b>  |              |                   | ND                   |
| <b>Number of reporting outpatient facilities</b>  |              |                   | ND                   |
| <b>Number of laboratories that perform AST and provide support to participating surveillance sites</b>            |              |                   | 24                   |

# Ejemplo: datos de implementación (1)




## Current status of the national AMR surveillance system



# Ejemplo: datos de implementación (2)




## **Current status of the national AMR surveillance system**



# AMR Data validation



- Your upload will follow several data validation steps:
  - Does your file meets GLASS requirements ?
  - Does your file presents blocking errors or non-blocking errors ?
- At each steps the system gives you a feedback
- At the end you choose to validate or not your data submission



➔ As soon as data uploaded, results are displayed in the reports



**Surveillance of antibacterial resistance in humans**

World Health Organization

HOME    MENU    USER\_TEST1    LOGOUT

GLASS welcomes the participation of all countries. Countries are invited to provide information on the status of implementation of national AMR surveillance and upload data on ABR, following the definitions provided in the GLASS: Manual for early implementation.

This database enables to:

- upload, manage and submit data
- access upload history
- access and download previously submitted data
- generate data reports

To continue, please read Terms of Use and complete the following information:

**Country information**    **GLASS implementation questionnaire**

GLASS Implementation questionnaire (\*.pdf)  
Questions related to the use of web-based internet GLASS platform should be sent to the email address: glass@who.int

**Aggregated AMR data**

Call for data on antimicrobial resistance will be open from July 1st 2016 to November 30th 2016

**Data upload**    **Upload history**    **AMR data base**    **Denominator Questionnaire**    **Reports**

For further information: [glass@who.int](mailto:glass@who.int)

A large red cursor arrow points towards the "Reports" button in the bottom navigation bar of the GLASS interface.

# Specific pathogen resistance to reported antibiotics

## Reports

| Country characteristics  | Data overview by specimen type        | AST by Antibiotic Class | AST by age, gender and origin | Percentile Distribution |       |
|--|---------------------------------------|-------------------------|-------------------------------|-------------------------|-------|
| Country *  | Who test                              | Year *                  | 2016                          |                         |       |
| Specimen *   | Blood                                 | Pathogen *              | Escherichia coli              |                         |       |
| Batch Id   |                                       | Gender                  |                               |                         |       |
| Age group  |                                       | Origin                  |                               |                         |       |
| Metric *   | Proportion excluding Unknown category |                         |                               |                         |       |
| Display option *   | Susceptible, Non Susceptible          |                         |                               |                         |       |
| <input type="button" value="Report"/>  |                                       |                         |                               |                         |       |
| Who test, 2016, Blood specimen, Escherichia coli pathogen, Origin : All, Gender : All, Age group : All, Batch Id : All, Metric : Proportion excluding Unknown category |                                       |                         |                               |                         |       |
| Antibiotic   | Susceptible                           | Nonsusceptible          | S+N                           | Unknown                 | Total |
| Penicillins  |                                       |                         |                               |                         |       |
| Ampicillin   | 725                                   | 646                     | 1371                          | 866                     | 2237  |
|  | 52.9 %                                | 47.1 %                  | 61.3 %                        | 38.7 %                  |       |
| Penicillins  | ND                                    | ND                      | ND                            | ND                      | ND    |
| Third-generation cephalosporins  |                                       |                         |                               |                         |       |
| Cefotaxime   | 254                                   | 35                      | 289                           | 1948                    | 2237  |
|  | 87.9 %                                | 12.1 %                  | 12.9 %                        | 87.1 %                  |       |
| Ceftazidime  | 2004                                  | 208                     | 2212                          | 25                      | 2237  |
|  | 90.6 %                                | 9.4 %                   | 98.9 %                        | 1.1 %                   |       |
| Ceftriaxone  | 1970                                  | 211                     | 2181                          | 56                      | 2237  |
|  | 90.3 %                                | 9.7 %                   | 97.5 %                        | 2.5 %                   |       |
| Third-generation cephalosporins  | 1999                                  | 224                     | 2223                          | 14                      | 2237  |

# Stratification by age groups



| AGE GROUPS : |          |        |        |        |        |
|--------------|----------|--------|--------|--------|--------|
|              | Subtotal | 254    | 35     | 289    | 1948   |
|              |          | 87.9 % | 12.1 % | 12.9 % | 87.1 % |
|              | <1       | 2      | 0      | 2      | 32     |
|              |          | 100 %  | 0 %    | 5.9 %  | 94.1 % |
|              | 01-04    | 0      | 0      | 0      | 4      |
|              |          | Nan %  | Nan %  | 0 %    | 100 %  |
|              | 05-14    | 0      | 0      | 0      | 6      |
|              |          | Nan %  | Nan %  | 0 %    | 100 %  |
|              | 15-24    | 2      | 0      | 2      | 38     |
|              |          | 100 %  | 0 %    | 5 %    | 95 %   |
|              | 25-34    | 3      | 0      | 3      | 54     |
|              |          | 100 %  | 0 %    | 5.3 %  | 94.7 % |
|              | 35-44    | 10     | 2      | 12     | 54     |
|              |          | 83.3 % | 16.7 % | 18.2 % | 81.8 % |
|              | 45-54    | 21     | 5      | 26     | 126    |
|              |          | 80.8 % | 19.2 % | 17.1 % | 82.9 % |
|              | 55-64    | 38     | 6      | 44     | 266    |
|              |          | 86.4 % | 13.7 % | 14.2 % | 85.8 % |
|              | 65-74    | 64     | 13     | 77     | 438    |
|              |          | 83.1 % | 16.9 % | 15 %   | 85 %   |
|              | 75-84    | 75     | 6      | 81     | 573    |
|              |          | 92.6 % | 7.4 %  | 12.4 % | 87.6 % |
|              | 85+      | 39     | 3      | 42     | 357    |
|              |          | 92.9 % | 7.1 %  | 10.5 % | 89.5 % |
|              | Unknown  | ND     | ND     | ND     | ND     |

# Rates per 1000 patients sampled if number of sampled patients is reported



| Who test, 2016, Genital specimen, Neisseria gonorrhoeae-Ciprofloxacin combination, Origin : All, Gender : All, Age group : All, Batch Id : All, Metric : Rates per 1000 patients with samples taken |             |                |      |         |       |                  |
|---|-------------|----------------|------|---------|-------|------------------|
| Stratification  | Susceptible | Nonsusceptible | S+N  | Unknown | Total | Sampled patients |
| <b>ORIGIN :</b>   |             |                |      |         |       |                  |
| Subtotal  | 32          | 292            | 324  | 6       | 330   | 7325             |
|   | 4.4         | 39.9           | 44.2 | 0.8     | 45.1  |                  |
| Hospital origin   | ND          | ND             | ND   | ND      | ND    | ND               |
| Community origin  | 30          | 290            | 320  | 6       | 326   | 7015             |
|   | 4.3         | 41.3           | 45.6 | 0.9     | 46.5  |                  |
| Unknown   | 2           | 2              | 4    | 0       | 4     | 310              |
|   | 6.5         | 6.5            | 12.9 | 0       | 12.9  |                  |
| <b>GENDER :</b>   |             |                |      |         |       |                  |
| Subtotal  | 32          | 292            | 324  | 6       | 330   | 7325             |
|   | 4.4         | 39.9           | 44.2 | 0.8     | 45.1  |                  |
| Male  | 28          | 240            | 268  | 4       | 272   | 5205             |
|   | 5.4         | 46.1           | 51.5 | 0.8     | 52.3  |                  |
| Female  | 4           | 50             | 54   | 2       | 56    | 1965             |
|   | 2           | 25.5           | 27.5 | 1       | 28.5  |                  |
| Other   | ND          | ND             | ND   | ND      | ND    | ND               |
| Unknown   | 0           | 2              | 2    | 0       | 2     | 155              |
|   | 0           | 12.9           | 12.9 | 0       | 12.9  |                  |

# Technical support to countries



---

# Flexibility to include ALL countries

→ Based on the recommendations from countries


# Ejemplo de resumen de datos RAM (1)



| Specimen | Data on number of tested patients | Pathogen                  | AST results | Age | Gender | Infection origin |
|----------|-----------------------------------|---------------------------|-------------|-----|--------|------------------|
| Blood    | 72                                | <i>Acinetobacter</i> spp. | ●           | ●   | ●      | ●                |
|          |                                   | <i>E. coli</i>            | ●           | ●   | ●      | ●                |
|          |                                   | <i>K. pneumoniae</i>      | ●           | ●   | ●      | ●                |
|          |                                   | <i>Salmonella</i> spp.    | ●           | ●   | ●      | ●                |
|          |                                   | <i>S. aureus</i>          | ●           | ●   | ●      | ●                |
|          |                                   | <i>S. pneumoniae</i>      | ●           | ●   | ●      | ●                |
| Urine    | 72                                | <i>E. coli</i>            | ●           | ●   | ●      | ●                |
|          |                                   | <i>K. pneumoniae</i>      | ●           | ●   | ●      | ●                |
| Stool    | 72                                | <i>Salmonella</i> spp.    | ●           | ●   | ●      | ●                |
| Genital  | 72                                | <i>Shigella</i> spp.      | ●           | ●   | ●      | ●                |
|          |                                   | <i>N. gonorrhoea</i>      | ●           | ●   | ●      | ●                |

## Data overview – collection between January and December 2016

| Specimen | Number of tested patients |                 |                | Number of patients with positive samples |                 |                |
|----------|---------------------------|-----------------|----------------|--|-----------------|----------------|
|          | Community origin          | Hospital origin | Unknown origin | Community origin                         | Hospital origin | Unknown origin |
| Blood    | -                         | -               | -              | <i>Acinetobacter</i> spp.                | -               | -              |
|          |                           |                 |                | <i>E. coli</i>                           | -               | -              |
|          |                           |                 |                | <i>K. pneumoniae</i>                     | -               | -              |
|          |                           |                 |                | <i>Salmonella</i> spp.                   | -               | -              |
|          |                           |                 |                | <i>S. aureus</i>                         | -               | -              |
|          |                           |                 |                | <i>S. pneumoniae</i>                     | -               | -              |
| Urine    | -                         | -               | -              | <i>E. coli</i>                           | -               | -              |
|          |                           |                 |                | <i>K. pneumoniae</i>                     | -               | -              |
|          |                           |                 |                | <i>Salmonella</i> spp.                   | -               | -              |
| Stool    | -                         | -               | -              | <i>Shigella</i> spp.                     | -               | -              |
|          |                           |                 |                | <i>N. gonorrhoea</i>                     | -               | -              |
| Genital  | -                         | -               | -              | -  | -               | -              |




# Ejemplo de resumen de datos RAM (2)



| Specimen | Data on number of tested patients | Pathogen                  | AST results | Age | Gender | Infection origin |
|----------|-----------------------------------|---------------------------|-------------|-----|--------|------------------|
| Blood    | 100                               | <i>Acinetobacter</i> spp. | ●           | ●   | ●      | ●                |
|          |                                   | <i>E. coli</i>            | ●           | ●   | ●      | ●                |
|          |                                   | <i>K. pneumoniae</i>      | ●           | ●   | ●      | ●                |
|          |                                   | <i>Salmonella</i> spp.    | ●           | ●   | ●      | ●                |
|          |                                   | <i>S. aureus</i>          | ●           | ●   | ●      | ●                |
|          |                                   | <i>S. pneumoniae</i>      | ●           | ●   | ●      | ●                |
| Urine    | 100                               | <i>E. coli</i>            | ●           | ●   | ●      | ●                |
|          |                                   | <i>K. pneumoniae</i>      | ●           | ●   | ●      | ●                |
| Stool    | 100                               | <i>Salmonella</i> spp.    | ●           | ●   | ●      | ●                |
| Genital  | 100                               | <i>N. gonorrhoea</i>      | ●           | ●   | ●      | ●                |

***Acinetobacter* spp. (n=72)**



## Data overview – collection between January and December 2016

| Specimen | Number of tested patients |                 |                | Number of patients with positive samples |                 |                |
|----------|---------------------------|-----------------|----------------|--|-----------------|----------------|
|          | Community origin          | Hospital origin | Unknown origin | Community origin                         | Hospital origin | Unknown origin |
| Blood    | -                         | -               | -              | <i>Acinetobacter</i> spp.                | -               | 72             |
|          |                           |                 |                | <i>E. coli</i>                           | -               | 405            |
|          |                           |                 |                | <i>K. pneumoniae</i>                     | -               | 126            |
|          |                           |                 |                | <i>Salmonella</i> spp.                   | -               | 122            |
|          |                           |                 |                | <i>S. aureus</i>                         | -               | 245            |
|          |                           |                 |                | <i>S. pneumoniae</i>                     | -               | 463            |
| Urine    | -                         | -               | -              | <i>E. coli</i>                           | -               | 252            |
|          |                           |                 |                | <i>K. pneumoniae</i>                     | -               | 47             |
| Stool    | -                         | -               | -              | <i>Salmonella</i> spp.                   | -               | 83             |
|          |                           |                 |                | <i>Shigella</i> spp.                     | -               | 110            |
| Genital  | -                         | -               | -              | <i>N. gonorrhoea</i>                     | -               | 413            |


# Ejemplo de resumen de datos RAM (3)



| Specimen | Number of tested patients | Pathogen               | AST results | Age | Gender | Infection origin |
|----------|---------------------------|------------------------|-------------|-----|--------|------------------|
| Blood    | ●                         | <i>A. baumannii</i>    | ●           | ●   | ●      | ●                |
|          |                           | <i>E. coli</i>         | ●           | ●   | ●      | ●                |
|          |                           | <i>K. pneumoniae</i>   | ●           | ●   | ●      | ●                |
|          |                           | <i>Salmonella</i> spp. | ●           | ●   | ●      | ●                |
|          |                           | <i>S. aureus</i>       | ●           | ●   | ●      | ●                |
|          |                           | <i>S. pneumoniae</i>   | ●           | ●   | ●      | ●                |
| Urine    | ●                         | <i>E. coli</i>         | ●           | ●   | ●      | ●                |
|          |                           | <i>K. pneumoniae</i>   | ●           | ●   | ●      | ●                |
| Stool    | ●                         | <i>Salmonella</i> spp. | ●           | ●   | ●      | ●                |
|          |                           | <i>Shigella</i> spp.*  | ●           | ●   | ●      | ●                |
| Genital  | ●                         | <i>N. gonorrhoea</i>   | ●           | ●   | ●      | ●                |

\* Data collected by the national system, but no positive samples were obtained.

## *Acinetobacter* spp. (n=169)




## Data overview – collection between January and June 2016

| Specimen | Number of tested patients | Pathogens        |                 |                | Number of patients with positive samples |                 |                |
|----------|---------------------------|------------------|-----------------|----------------|--|-----------------|----------------|
|          |                           | Community origin | Hospital origin | Unknown origin | Community origin                         | Hospital origin | Unknown origin |
| Blood    | 38938                     | 9434             | -               | -              | Acinetobacter spp.                       | 27              | 142            |
|          |                           |                  | -               | -              | <i>E. coli</i>                           | 885             | 219            |
|          |                           |                  | -               | -              | <i>K. pneumoniae</i>                     | 306             | 116            |
|          |                           |                  | -               | -              | <i>Salmonella</i> spp.                   | 32              | 2              |
|          |                           |                  | -               | -              | <i>S. aureus</i>                         | 195             | 195            |
|          |                           |                  | -               | -              | <i>S. pneumoniae</i>                     | 11              | 3              |
| Urine    | 31426                     | 8988             | -               | -              | <i>E. coli</i>                           | 3637            | 799            |
|          |                           |                  | -               | -              | <i>K. pneumoniae</i>                     | 491             | 321            |
| Stool    | 4777                      | 4283             | -               | -              | <i>Salmonella</i> spp.                   | 65              | 6              |
|          |                           |                  | -               | -              | <i>Shigella</i> spp.                     | -               | -              |
| Genital  | -                         | -                | -               | -              | <i>N. gonorrhoea</i>                     | -               | -              |


# Cont. ejemplo de resumen de datos (2)



Blood – Hospital infection origin (n=9434)



**Blood**  
***Acinetobacter baumannii***




# Interpretación de los resultados

= dependiente de las prácticas de utilización de métodos diagnósticos



Proof of principle study to improve sampling habits



Nienke van de Sande

Technical officer AMR, WHO Regional office for Europe,  
Denmark



PoP has the goal to improve

Use of **microbiological diagnostics** to identify pathogens and guide therapeutic decisions.

Appropriate selection & collection of specimens

Accurate and timely **testing & reporting** of results


Responsible & informed **prescribing** of antimicrobials



# Mejorar el uso de métodos diagnósticos = ayuda a la vigilancia!!



Proof of principle study to improve sampling habits



Nienke van de Sande

Technical officer AMR, WHO Regional office for Europe,  
Denmark



PoP has the goal to improve

Use of **microbiological diagnostics** to identify pathogens and guide therapeutic decisions.

Appropriate selection & collection of specimens

Accurate and timely **testing & reporting** of results

Responsible & informed **prescribing** of antimicrobials

**Diagnostic stewardship**

A guide to implementation in antimicrobial resistance surveillance sites



# Access to GLASS data



- ➔ IT data platform hosted in WHO
  - ➔ The reports with specific country data are visible for GLASS users with passwords:
    - only for your country users
    - for the staff of specific WHO region
    - for the WHO HQ staff

# Concluding remarks

---



- ➔ Need for good diagnostic practices for improving quality of data
- ➔ GLASS as a global tool for
  - data sharing
  - Data analysis & reporting
- ➔ Participation in GLASS
  - Share data on common indicators
  - Shape and inform future GLASS development

# Gracias



→ [glass@who.int](mailto:glass@who.int)

